00:00A popular weight loss and diabetes drug might be doing something nobody expected for people with
00:05asthma. Simaglutide, the active ingredient in Ozempic and Wagovi, was linked to nearly 40%
00:11fewer asthma attacks in a large real-world study presented at the European Respiratory Society
00:17Congress in Barcelona. It was also associated with about 20% fewer COPD flare-ups. The research,
00:24led by Professor Chloe Bloom at Imperial College London, used UK medical records to
00:29run four parallel studies, each following between 20,000 and 22,000 people who started GLP-1
00:36treatments compared to those on other diabetes medicines. Researchers believe the anti-inflammatory
00:42effects of GLP-1 drugs may be behind the benefit, extending well beyond their known effects on
00:47blood sugar and weight. Experts caution that clinical trials are still needed, and people
00:52shouldn't try to self-prescribe for these benefits. Disclosure. This video contains stock footage and
00:57content created or enhanced using AI-assisted tools.
Comments